Your browser doesn't support javascript.
loading
Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.
Liu, Jingjing; Prager-van der Smissen, Wendy J C; Collée, J Margriet; Bolla, Manjeet K; Wang, Qin; Michailidou, Kyriaki; Dennis, Joe; Ahearn, Thomas U; Aittomäki, Kristiina; Ambrosone, Christine B; Andrulis, Irene L; Anton-Culver, Hoda; Antonenkova, Natalia N; Arndt, Volker; Arnold, Norbert; Aronson, Kristan J; Augustinsson, Annelie; Auvinen, Päivi; Becher, Heiko; Beckmann, Matthias W; Behrens, Sabine; Bermisheva, Marina; Bernstein, Leslie; Bogdanova, Natalia V; Bogdanova-Markov, Nadja; Bojesen, Stig E; Brauch, Hiltrud; Brenner, Hermann; Briceno, Ignacio; Brucker, Sara Y; Brüning, Thomas; Burwinkel, Barbara; Cai, Qiuyin; Cai, Hui; Campa, Daniele; Canzian, Federico; Castelao, Jose E; Chang-Claude, Jenny; Chanock, Stephen J; Choi, Ji-Yeob; Christiaens, Melissa; Clarke, Christine L; Couch, Fergus J; Czene, Kamila; Daly, Mary B; Devilee, Peter; Dos-Santos-Silva, Isabel; Dwek, Miriam; Eccles, Diana M; Eliassen, A Heather.
Afiliação
  • Liu J; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Prager-van der Smissen WJC; Institute of Medical and Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, China.
  • Collée JM; Department of Medical Oncology, Family Cancer Clinic, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Bolla MK; Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands.
  • Wang Q; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Michailidou K; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Dennis J; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Ahearn TU; Biostatistics Unit, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
  • Aittomäki K; Cyprus School of Molecular Medicine, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
  • Ambrosone CB; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
  • Andrulis IL; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA.
  • Anton-Culver H; Department of Clinical Genetics, Helsinki University Hospital, University of Helsinki, Helsinki, Finland.
  • Antonenkova NN; Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Arndt V; Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada.
  • Arnold N; Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada.
  • Aronson KJ; Department of Epidemiology, Genetic Epidemiology Research Institute, University of California Irvine, Irvine, CA, USA.
  • Augustinsson A; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
  • Auvinen P; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Becher H; Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
  • Beckmann MW; Institute of Clinical Molecular Biology, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany.
  • Behrens S; Department of Public Health Sciences, and Cancer Research Institute, Queen's University, Kingston, ON, Canada.
  • Bermisheva M; Department of Cancer Epidemiology, Clinical Sciences, Lund University, Lund, Sweden.
  • Bernstein L; Cancer Center, Kuopio University Hospital, Kuopio, Finland.
  • Bogdanova NV; Institute of Clinical Medicine, Oncology, University of Eastern Finland, Kuopio, Finland.
  • Bogdanova-Markov N; Translational Cancer Research Area, University of Eastern Finland, Kuopio, Finland.
  • Bojesen SE; Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Brauch H; Institute of Biometry and Clinical Epidemiology, Charité -Universitätsmedizin Berlin, Berlin, Germany.
  • Brenner H; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Briceno I; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Brucker SY; Institute of Biochemistry and Genetics, Ufa Federal Research Centre of the Russian Academy of Sciences, Ufa, Russia.
  • Brüning T; Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA, USA.
  • Burwinkel B; N.N. Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus.
  • Cai Q; Department of Radiation Oncology, Hannover Medical School, Hannover, Germany.
  • Cai H; Gynaecology Research Unit, Hannover Medical School, Hannover, Germany.
  • Campa D; Institute of Human Genetics, University of Münster, Münster, Germany.
  • Canzian F; Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Castelao JE; Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark.
  • Chang-Claude J; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Chanock SJ; Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart, Germany.
  • Choi JY; iFIT-Cluster of Excellence, University of Tübingen, Tübingen, Germany.
  • Christiaens M; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany.
  • Clarke CL; Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Couch FJ; Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Czene K; Institute of Human Genetics, Pontificia Universidad Javeriana, Bogota, Colombia.
  • Daly MB; Medical Faculty, Universidad de La Sabana, Bogota, Colombia.
  • Devilee P; Department of Gynecology and Obstetrics, University of Tübingen, Tübingen, Germany.
  • Dos-Santos-Silva I; Institute for Prevention and Occupational Medicine of the German Social Accident Insurance, Institute of the Ruhr University Bochum (IPA), Bochum, Germany.
  • Dwek M; Molecular Epidemiology Group, C080, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Eccles DM; Molecular Biology of Breast Cancer, University Womens Clinic Heidelberg, University of Heidelberg, Heidelberg, Germany.
  • Eliassen AH; Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Sci Rep ; 10(1): 9688, 2020 06 16.
Artigo em Inglês | MEDLINE | ID: mdl-32546843
ABSTRACT
In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR = 1.035, 95% CI = 0.859-1.246, P = 0.718 and OR = 0.798, 95% CI = 0.482-1.322, P = 0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Thus, although involved in breast cancer progression, HOXB13 is not a material breast cancer susceptibility gene.
Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Estudo de etiologia / Estudo observacional / Fatores de risco Idioma: Inglês Revista: Sci Rep Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Holanda

Similares

MEDLINE

...
LILACS

LIS

Texto completo: Disponível Coleções: Bases de dados internacionais Base de dados: MEDLINE Tipo de estudo: Estudo de etiologia / Estudo observacional / Fatores de risco Idioma: Inglês Revista: Sci Rep Ano de publicação: 2020 Tipo de documento: Artigo País de afiliação: Holanda